Nantes University Hospital

Inotuzumab ozogamicin with low-dose chemotherapy showed efficacy in first-line treatment of older patients with CD22-positive, Philadelphia chromosome–negative B-cell precursor ALL, achieving 73% 1-year overall survival and 66% 1-year relapse-free survival. High-risk cytogenetics and higher MRD2 levels were associated with poorer outcomes, while higher CD22 expression improved survival.

OSE Immunotherapeutics reports H1 2024 results with €82.5 million income, strategic partnerships with AbbVie and Boehringer Ingelheim, and €80.7 million cash position. Clinical highlights include positive Phase 1/2 results for OSE-279 and Lusvertikimab, and the launch of the Artemia Phase 3 study for Tedopi®.

OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® in second-line NSCLC, targeting HLA-A2+ patients with secondary resistance to ICI, aiming for regulatory registration in Europe and North America.